Thompson Siegel & Walmsley’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Thompson Siegel & Walmsley’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-383	Closed	-$40K	–	832
2017 Q4	$40K	Hold	383	–	–	﹤0.01%	571
2017 Q3	$43K	Hold	383	–	–	﹤0.01%	546
2017 Q2	$43K	Buy	+383	New	+$43.3K	﹤0.01%	555

Other funds holding TARO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Fort LP Chevy Chase, Maryland $39.6M AUM 37.11% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Thompson Siegel & Walmsley's TARO Position: Q1 2018 in Review

Thompson Siegel & Walmsley sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q1 2018, closing a stake of 383 shares — an estimated $40K sold.

Thompson Siegel & Walmsley first reported a position in TARO in Q2 2017 and held it in 3 quarters. The position peaked at $43K in Q3 2017. 109 funds tracked by Wall St. Rank hold TARO as of Q1 2018.

Thompson Siegel & Walmsley reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q1 2018 after selling out during the quarter.
Thompson Siegel & Walmsley sold 383 Taro Pharmaceutical Industries Ltd. shares in Q1 2018, an estimated $40K.
Thompson Siegel & Walmsley first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2017 and held it in 3 quarters.
Thompson Siegel & Walmsley's Taro Pharmaceutical Industries Ltd. position peaked at $43K in Q3 2017.
109 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2018.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2018, filed 8 May 2018.